Imbruvica fails Phase III pancreatic cancer trial
A late-stage trial testing AbbVie’s Imbruvica in combination with chemotherapy for metastatic pancreatic adenocarcinoma (cancer) has failed to meet its primary endpoint.
Read More
Tag: metastatic pancreatic adenocarcinoma
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
